Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus verapamil ‐ charring ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 7
Studies not reported
Very low
Scar severity assessed by health professionals · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes scar severity ‐ Non‐Ablative Fractional Laser (NAFL) versus no… compared with no treatment (very low certainty).
1 finding from 1 review
RR 2 [0.85, 4.69]
Studies not reported
Very low
Scar severity ‐ NAFL versus no treatment ‐ patient global assessment measured on a VAS ranging from 0 to 100 mm (0 = as normal skin and 100 = worst possible scar) ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Scar severity ‐ erbium laser versus TAC ‐ VBS (Higher scores = worse scar appearance) ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ scar worsening ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ NAFL… compared with no treatment (very low certainty).
1 finding from 1 review
RR 7
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ hyperpigmentation ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ NAFL… compared with no treatment (very low certainty).
1 finding from 1 review
RR 3
Studies not reported
Very low
All‐cause mortality · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes all‐cause mortality compared with no intervention (very low certainty).
1 finding from 1 review
Upper gastrointestinal bleeding · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes upper gastrointestinal bleeding compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of congestive hypertensive gastropathy · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of bleeding from gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oesophageal variceal bleeding · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes oesophageal variceal bleeding compared with no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review
Global state: clinically important change in global state · people with the acute phase of schizophrenia
It is very uncertain whether magnetic seizure therapy plus standard care changes global state: clinically important change assessed by: number of… compared with electroconvulsive therapy plus standard care (very low certainty).
1 finding from 1 review
Cognitive functioning: clinically important change ‐ not measured · people with the acute phase of schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: clinically important adverse effectsassessed by: number of participants with a delayed memory deficitStudy duration: 4 weeks · people with the acute phase of schizophrenia
It is very uncertain whether magnetic seizure therapy plus standard care changes adverse effects: clinically important adverse effectsassessed by:… compared with electroconvulsive therapy plus standard care (very low certainty).
1 finding from 1 review
Quality of life: clinically important change ‐ not measured · people with the acute phase of schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Social functioning: clinically important change ‐ not measured · people with the acute phase of schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropout · people with the acute phase of schizophrenia
It is very uncertain whether magnetic seizure therapy plus standard care changes leaving the study early: any reasonassessed by: number of dropouts… compared with electroconvulsive therapy plus standard care (very low certainty).
1 finding from 1 review